Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URLi Dosing Timing in Medtronic 780G for T1DM
NCT06600776Phase 4Not yet recruiting
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Oct 2024
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin lispro in type 1 diabetes mellitus (T1D), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoint: Percentage of Time in Glucose Range (70-180 mg/dL) at 4 weeks. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
insulin lispro
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06600776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06600776.